An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis
•Current therapy improvement trends include drug combinations and the use of carriers.•Novo discovery and repositioning of drugs lead the researches on novel therapies.•Plants are being widely explored as a source of new drug discovery.•Different strategies are being developed to improve topical pho...
Gespeichert in:
Veröffentlicht in: | Acta tropica 2021-09, Vol.221, p.105988-105988, Article 105988 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Current therapy improvement trends include drug combinations and the use of carriers.•Novo discovery and repositioning of drugs lead the researches on novel therapies.•Plants are being widely explored as a source of new drug discovery.•Different strategies are being developed to improve topical photodynamic therapy.•Most in vivo tests use female BALB/c mice infected in the base of tail with L. amazonensis.
Leishmaniasis is a Neglected Tropical Diseases caused by protozoan parasites of the genus Leishmania. It is a major health problem in many tropical and subtropical regions of the world and can produce three different clinical manifestations, among which cutaneous leishmaniasis has a higher incidence in the world than the other clinical forms. There are no recognized and reliable means of chemoprophylaxis or vaccination against infections with different forms of leishmaniasis. In addition, chemotherapy, unfortunately, remains, in many respects, unsatisfactory. Therefore, there is a continuing and urgent need for new therapies against leishmaniasis that are safe and effective in inducing a long-term cure. This review summarizes the latest advances in currently available treatments and improvements in the development of drug administration. In addition, an analysis of the in vivo assays was performed and the challenges facing promising strategies to treat CL are discussed. The treatment of leishmaniasis will most likely evolve into an approach that uses multiple therapies simultaneously to reduce the possibility of developing drug resistance. There is a continuous effort to discover new drugs to improve the treatment of leishmaniasis, but this is mainly at the level of individual researchers. Undoubtedly, more funding is needed in this area, as well as greater participation of the pharmaceutical industry to focus efforts on the development of chemotherapeutic agents and vaccines for this and other neglected tropical diseases.
[Display omitted] |
---|---|
ISSN: | 0001-706X 1873-6254 |
DOI: | 10.1016/j.actatropica.2021.105988 |